SiPake Pharmaceutical

The China National Intellectual Property Administration (CNIPA) has declared the compound patent CN200980116857.7 for Eli Lilly’s (NYSE: LLY) JAK inhibitor Olumiant (baricitinib) invalid in its entirety, as per a recent public document. The decision came after a challenge from Nanjing SiPake Pharmaceutical Technology Co., Ltd. Baricitinib, a JAK1/JAK2 inhibitor originally…